-
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
-
Rodríguez and colleagues report on a prospectively enrolled cohort of 235 consecutive patients admitted to two ICUs in Spain who required mechanical ventilation for at least 48 hours and had indications for ventilatory support other than respiratory infection or acute exacerbation of chronic obstructive pulmonary disease (COPD).
-
Bedside ultrasound is increasingly being performed in the intensive care unit (ICU) for a variety of purposes including guiding volume resuscitation, central line placement, and marking pleural fluid collections for drainage.
-
When patients sustain a sudden cardiac arrest, they require immediate life-saving therapies to restart cardiac function and prevent secondary anoxic brain injury.
-
-
Coccidioidal infections are always unique the travel history often provides the right clue for the practitioner but first you have to think to ask the right question.
-
In a prospective observational study, investigators of the HIV-CAUSAL Collaboration evaluated data from participating HIV clinics in Europe and the U.S. Veterans Administration system to determine the optimal CD4+ T cell count at which combination antiretroviral therapy (cART) should be initiated.
-
GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16, 18] Vaccine, Recombinant) previously received FDA approval for prevention of cervical, vulvar, and vaginal cancer and associated precancerous lesions, and for prevention of genital warts in males and females 9-26 years of age.
-
A retrospective study was conducted of 563 children who presented over the last decade to two pediatric immunodeficiency centers in the United Kingdom.
-
ZOSTAVAX®, which had previously received FDA approval for prevention of herpes zoster (HZ) and post-herpetic neuralgia in individuals 60 years of age and older, had its approval extended to include people 50-59 years of age on March 24, 2011.